Global Access and Impact: Closing the Gaps Schedule

Global Access to Immunotherapy: Closing the Gaps

Workshop Agenda

Dec. 9–10, 2020

Enduring Materials from the Workshop are accessible on this page.  Please click on the links below to access presentation slides and video.

If you have questions about "Global Access to Cancer Immunotherapy: Closing the Gaps" enduring materials, please contact fdewalt@sitcancer.org. 

no_symbol.pngSITC is committed to sharing presentations from its programs for the advancement of the field but respects faculty requests to maintain confidentiality of their unpublished data and therefore will be unable to share presentations with this symbol

 

Schedule

Wednesday, Dec. 9, 2020

9:00 9:20 a.m.

Welcome 
David Kaufman MD, PhD – Third Rock Ventures
Samir Khleif, MD – Georgetown University 

 Session 1: Setting the Stage

9:20 9:40 a.m.

African access initiative insights: the promise, potential, and implications of cancer immunotherapies in Africa
Jennifer Dent, MBA – BIO Ventures for Global Health 

9:40  10:00 a.m.

Barriers and opportunities for cancer immunotherapy in Africa
Nestory Masalu, MD – Bugando Medical Center

10:00  10:20 a.m.

Access to immunotherapy in Mexico: Mission impossible?
Nora Sobrevilla-Moreno, MD – Instituto Nacional de Cancerología

10:20 10:50 a.m.

Panel discussion

Moderator:
Olufunmilayo Olopade, MD, FACP – University of Chicago 

Panelists:
Jennifer Dent, MBA – BIO Ventures for Global Health
Nestory Masalu, MD – Bugando Medical Center 
Nora Sobrevilla-Moreno, MD – Instituto Nacional de Cancerología
Clarissa Mathias , MD, PhD – NOB/Oncoclínicas

10:50 11:00 a.m.

Break 

Session 2: Challenges to Global Immunotherapy Access

11:00 11:20 a.m.

Capacity considerations for innovative cancer medicines
Marko Spasic, MD – Parker Institute for Cancer Immunotherapy 

11:20 11:40 a.m.


no_symbol.png

Innovation in cancer care in sub-Saharan Africa: a phase I study of rituximab hyalronidase at the Uganda Cancer Institute
Thomas Uldrick, MD, MS – Fred Hutchinson Cancer Research Center 

11:40 12:00 p.m.

Immuno-oncology research in Central Eastern Europe – population access and site readiness for immunotherapy
Anna Baran, MD – KCR Consulting
Yaroslav Shparyk, MD, phD – Lviv State Oncological Regional Medical and Diagnostic Center 

12:00 - 1:00 p.m.

Panel discussion

Moderator:
Taofeek Owonikoko, MD, PhD, MSCR – Emory University 

Panelists: 
Marko Spasic, MD – Parker Institute for Cancer Immunotherapy 
Thomas Uldrick, MD, MS – Fred Hutchinson Cancer Research Center
Anna Baran, MD – KCR Consulting
Oscar Arrieta, MD, MS – Instituto Nacional de Cancerología
Muhammad Habeebu – NSIA-LUTH Cancer Centre/University of Lagos  
Alicia van der Laat, MD – Hospital Mexico, Costa Rica   
Yaroslav Shparyk, MD, PhD – Lviv State Oncological Regional Medical and Diagnostic Center

1:00 p.m.

Day 1 Closing remarks
David Kaufman, MD, PhD – Third Rock Ventures 


Thursday, Dec. 10, 2020

Session 3: Vision for Products with Impact and Sustainable Access

9:00 – 9:30 a.m.

Round Table: PD-1 checkpoint therapies from China: local experience and plans for emerging markets

Moderator:
Wenru Song, MD, PhD – Kira Pharma

Panelists:
Shirley Zhao – CStone Pharmaceuticals
Yong Ben, MD, MBA – BeiGene
Sheng Yao, MD – Shanghai Junshi Biosciences Co.

9:30 9:50 a.m.

Barriers and approaches to cancer immunotherapy in LMICs
Ute Dugan, MD, PhD – Parker Institute for Cancer Immunotherapy
Phangisile Mtshali – Bristol-Myers Squibb Foundation 

9:50 10:10 a.m.

Bintrafusp Alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in HPV–associated malignancies
Claudia-Nanette Gann, MD – EMD Serono

10:10  10:30 a.m.

Roche perspective on global access to cancer therapies, including I-O
Frank Loeffler – Roche
Philip Anderson, MD – Roche

10:30 10:50 a.m.

Panel discussion

Moderator:
Phangisile Mtshali – Bristol-Myers Squibb Foundation 

Panelists:
Ute Dugan, MD, PhD – Parker Institute for Cancer Immunotherapy
Claudia-Nanette Gann, MD – EMD Serono
Frank Loeffler – Roche
Philip Anderson, MD – Roche

10:50 11:00 a.m.

Break

Session 4: Scientific Questions That Need to be Answered in LMIC’s

11:00 11:20 a.m.

Presentation and survival from breast cancer in SSA
Nixon Niyonzima, MD – Uganda Cancer Institute

11:20 11:40 a.m.

Evaluation of immune checkpoint inhibitors in medically vulnerable populations: challenges and opportunities for translational research
Elad Sharon, MD, MPH – National Cancer Institute

11:40 12:00 p.m.

 

Cervical cancer and checkpoint blockade
Alfonso Dueñas – Instituto Nacional de Cancerología

12:00 - 12:20
p.m.

Panel discussion

Moderator:
Verna Vanderpuye, MD – Bu Teaching Hospital

Panelists:
Ramya Ramaswami, MBBS, MPH – National Cancer Institute 
Elad Sharon, MD, MPH – National Cancer Institute
Nixon Niyonzima, MD – Uganda Cancer Institute
Alfonso Dueñas – Instituto Nacional de Cancerología
Adedayo Joseph, MD – NSIA-LUTH Cancer Center
Thomas Uldrick, MD, MS – Fred Hutchinson Cancer Research Center

Session 5: Wrap-up: Next Steps and Line of Sight to Recommendations

12:20 - 12:40 
p.m.

Accelerating access to cancer immunotherapies: Learning from the global health experience of CHAI, American Cancer Society, and Allied Against Cancer
Emily Kobayashi – Clinton Health Access Initiative 

12:40 - 1:00 p.m

Round Table: Networking to increase cooperation between regions: Clinical trials, sharing of epidemiologic data, and other areas for collaboration

Moderator:
Nora Sobrevilla-Moreno, MD – Instituto Nacional de Cancerología

Panelists: 
Marisa Nimrod, MD – Caribbean Association of Hematology and Oncology
Hanna Simonds, MBChB, MRCP, FRCR – Stellenbosch University
Oscar Arrieta, MD, MS – Instituto Nacional de Cancerología
Addu Bounedja – Saad Dahlab University

1:00 - 1:25 p.m.

Panel discussion

Moderator:
Fredrick Chite Asirwa, MD – International Cancer Institute Eldoret

Panelists:
Satish Gopal, MD, MPH – National Cancer Institute
David Kaufman, MD, PhD – Third Rock Ventures
Samir Khleif, MD – Georgetown University 
Verna Vanderpuye, MD – Bu Teaching Hospital
Nora Sobrevilla-Moreno, MD – Instituto Nacional de Cancerología
Tolulope Adewole, MBBS – NSIA-LUTH Cancer Center
Zainab Mohamed, MBChB, MMed – University of Cape Town
Ute Dugan, MD, PhD – Parker Institute for Cancer Immunotherapy

1:25 - 1:30 p.m.

Conclusion and thank you
David Kaufman, MD, PhD – Third Rock Ventures